
The association of priapism with trazodone is reviewed based on data reported to the Food and Drug Administration. The data suggest that priapism may be most likely to occur within the first 28 days of treatment and that the majority of cases occur with doses of 150 mg/day or less. All age groups appear to be vulnerable to this adverse effect. Patients should be informed of this potential side effect and instructed to discontinue the medication if any unusual erectile problems develop.
Psychiatry, Adult, Male, PSYCHIATRY, SCI, PSYCHOLOGY, CLINICAL, Time Factors, Adolescent, Dose-Response Relationship, Drug, Psychology, Clinical, Age Factors, Middle Aged, PSYCHIATRY, SSCI, Clinical, SCI, Trazodone, SSCI, Psychology, Humans, Priapism, 11 Medical and Health Sciences
Psychiatry, Adult, Male, PSYCHIATRY, SCI, PSYCHOLOGY, CLINICAL, Time Factors, Adolescent, Dose-Response Relationship, Drug, Psychology, Clinical, Age Factors, Middle Aged, PSYCHIATRY, SSCI, Clinical, SCI, Trazodone, SSCI, Psychology, Humans, Priapism, 11 Medical and Health Sciences
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 75 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 1% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
